Aldose reductase, oxidative stress and diabetic cardiovascular complications

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 10, Issue 3, 2012, Pages 234-240

  Vedantham, Srinivasan ^a   Ananthakrishnan, Radha ^a   Schmidt, Ann Marie ^a   Ramasamy, Ravichandran ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Advanced glycation end products; Aldose reductase; Aldose reductase inhibitors; Atherosclerosis; Cardiovascular complications; Diabetes; Hyperglycemia; Ischemia reperfusion; Oxidative stress; Polyol pathway

Indexed keywords

ALDEHYDE REDUCTASE; EPALRESTAT; REACTIVE OXYGEN METABOLITE; TOLRESTAT; ZOPOLRESTAT;

AGING; ARTICLE; ATHEROSCLEROSIS; BIOCHEMISTRY; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG MECHANISM; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; NONHUMAN; OXIDATIVE STRESS;

EID: 84864543034     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152512802651097     Document Type: Article

References (80)

1. Hsueh, W.; Abel, E.D.; Breslow, J.L.; Maeda, N.; Davis, R.C.; Fisher, E.A.; Dansky, H.; McClain, D.A.; McIndoe, R.; Wassef, M.K.; Rabadan-Diehl, C.; Goldberg, I.J. Recipes for creating animal models of diabetic cardiovascular disease. Circ. Res., 2007, 100(10), 1415-1427.
2. Ido, Y.; Nyengaard, J.R.; Chang, K.; Tilton, R.G.; Kilo, C.; Mylari, B.L.; Oates, P.J.; Williamson, J.R. Early neural and vascular dysfunctions in diabetic rats are largely sequelae of increased sorbitol oxidation. Antioxid. Redox Signal., 2010, 12(1), 39-51.
3. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2001, 414(6865), 813-820.
4. Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 2005, 54(6), 1615-1625.
5. Ceriello, A.; Motz, E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol., 2004, 24(5), 816-823.
6. Ido, Y. Pyridine nucleotide redox abnormalities in diabetes. Antioxid. Redox Signal., 2007, 9(7), 931-942.
7. Nishikawa, T.; Edelstein, D.; Du, X.L.; Yamagishi, S.; Matsumura, T.; Kaneda, Y.; Yorek, M.A.; Beebe, D.; Oates, P.J.; Hammes, H.P.; Giardino, I.; Brownlee, M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 2000, 404(6779), 787-790.
8. Whiteside, C.I. Cellular mechanisms and treatment of diabetes vascular complications converge on reactive oxygen species. Curr. Hypertens. Rep., 2005, 7(2), 148-154.
9. Rondeau, J.M.; Tete-Favier, F.; Podjarny, A.; Reymann, J.M.; Barth, P.; Biellmann, J.F.; Moras, D. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase. Nature, 1992, 355(6359), 469-472.
10. Jez, J.M.; Penning, T.M. The aldo-keto reductase (AKR) superfamily: an update. Chem. Biol. Interact., 2001, 130-132(1-3), 499-525.
11. Petrash, J.M.; Tarle, I.; Wilson, D.K.; Quiocho, F.A. Aldose reductase catalysis and crystallography. Insights from recent advances in enzyme structure and function. Diabetes, 1994, 43(8), 955-959.
12. Grimshaw, C.E.; Bohren, K.M.; Lai, C.J.; Gabbay, K.H. Human aldose reductase: rate constants for a mechanism including interconversion of ternary complexes by recombinant wild-type enzyme. Biochemistry, 1995, 34(44), 14356-14365.
13. Wendt, T.; Bucciarelli, L.; Qu, W.; Lu, Y.; Yan, S.F.; Stern, D.M.; Schmidt, A.M. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr. Atheroscler. Rep., 2002, 4(3), 228-237.
14. Oates, P.J. Polyol pathway and diabetic peripheral neuropathy. Int. Rev. Neurobiol., 2002, 50, 325-392.
15. Tilton, R.G. Diabetic vascular dysfunction: links to glucoseinduced reductive stress and VEGF. Microsc. Res. Tech., 2002, 57(5), 390-407.
16. Ishii, H.; Tada, H.; Isogai, S. An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured mesangial cells. Diabetologia, 1998, 41(3), 362-364.
17. Trueblood, N.; Ramasamy, R. Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am. J. Physiol., 1998, 275(1 Pt. 2), H75-83.
18. Baynes, J.W. Role of oxidative stress in development of complications in diabetes. Diabetes, 1991, 40(4), 405-412.
19. Williamson, J.R.; Kilo, C.; Ido, Y. The role of cytosolic reductive stress in oxidant formation and diabetic complications. Diabetes Res. Clin Pract., 1999, 45(2-3), 81-82.
20. Koya, D.; King, G.L. Protein kinase C activation and the development of diabetic complications. Diabetes, 1998, 47(6), 859-866.
21. Williamson, J.R.; Chang, K.; Frangos, M.; Hasan, K.S.; Ido, Y.; Kawamura, T.; Nyengaard, J.R.; van den Enden, M.; Kilo, C.; Tilton, R.G. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes, 1993, 42(6), 801-813.
22. Ido, Y.; Chang, K.; Woolsey, T.A.; Williamson, J.R. NADH: sensor of blood flow need in brain, muscle, and other tissues. FASEB J., 2001, 15(8), 1419-1421.
23. Cheng, H.M.; Gonzalez, R.G. The effect of high glucose and oxidative stress on lens metabolism, aldose reductase, and senile cataractogenesis. Metabolism, 1986, 35(4), 10-14.
24. Ramana, K.V.; Friedrich, B.; Tammali, R.; West, M.B.; Bhatnagar, A.; Srivastava, S.K. Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes, 2005, 54(3), 818-829.
25. Yamaoka, T.; Nishimura, C.; Yamashita, K.; Itakura, M.; Yamada, T.; Fujimoto, J.; Kokai, Y. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia, 1995, 38(3), 255-261.
26. Vikramadithyan, R.K.; Hu, Y.; Noh, H.L.; Liang, C.P.; Hallam, K.; Tall, A.R.; Ramasamy, R.; Goldberg, I.J. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest., 2005, 115(9), 2434-2443.
27. Wu, L.; Vikramadithyan, R.; Yu, S.; Pau, C.; Hu, Y.; Goldberg, I.J.; Dansky, H.M. Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis. J. Lipid Res., 2006, 47(10), 2215-2222.
28. Srivastava, S.; Vladykovskaya, E.; Barski, O.A.; Spite, M.; Kaiserova, K.; Petrash, J.M.; Chung, S.S.; Hunt, G.; Dawn, B.;, Bhatnagar, A. Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice. Circ. Res., 2009, 105(8), 793-802.
29. Chen, C.H.; Budas, G.R.; Churchill, E.N.; Disatnik, M.H.; Hurley, T.D.; Mochly-Rosen, D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science, 2008, 321(5895), 1493-1495.
30. Vedantham, S.; Noh, H.L.; Ananthakrishnan, R.; Son, N.; Hallam, K.M.; Hu, Y.; Yu, S.; Shen, X.; Rosario, R.; Lu, Y.; Ravindranath, T.; Drosatos, K.; Huggins, L.A.; Schmidt, A.M.; Goldberg, I.J.; Ramasamy, R. Human Aldose Reductase Expression Accelerates Atherosclerosis in Diabetic apoE-/-Mice. Arterioscler. Thromb. Vasc. Biol., 2011, 31(8), 1805-1813.
31. Gleissner, C.A.; Sanders, J.M.; Nadler, J.; Ley, K. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2008, 28(6), 1137-1143.
32. Harja, E.; Bu, D.X.; Hudson, B.I.; Chang, J.S.; Shen, X.; Hallam, K.; Kalea, A.Z.; Lu, Y.; Rosario, R.H.; Oruganti, S.; Nikolla, Z.; Belov, D.; Lalla, E.; Ramasamy, R.; Yan, S.F.; Schmidt, A.M. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/-mice. J. Clin. Invest., 2008, 118(1), 183-194.
33. Dan, Q.; Wong, R.; Chung, S.K.; Chung, S.S.; Lam, K.S. Interaction between the polyol pathway and non-enzymatic glycation on aortic smooth muscle cell migration and monocyte adhesion. Life Sci., 2004, 76(4), 445-459.
34. Hwang, Y.C.; Sato, S.; Tsai, J.Y.; Yan, S.; Bakr, S.; Zhang, H.; Oates, P.J.; Ramasamy, R. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J., 2002, 16(2), 243-245.
35. Hwang, Y.C.; Kaneko, M.; Bakr, S.; Liao, H.; Lu, Y.; Lewis, E.R.; Yan, S.; Ii, S.; Itakura, M.; Rui, L.; Skopicki, H.; Homma, S.; Schmidt, A.M.; Oates, P.J.; Szabolcs, M.; Ramasamy, R. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J., 2004, 18(11), 1192-1199.
36. Ramasamy, R.; Oates, P.J.; Schaefer, S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes, 1997, 46(2), 292-300.
37. Ramasamy, R.; Trueblood, N.; Schaefer, S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am. J. Physiol., 1998, 275(1 Pt. 2), H195-203.
38. Ramasamy, R.; Liu, H.; Oates, P.J.; Schaefer, S. Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor zopolrestat. Cardiovasc. Res., 1999, 42(1), 130-139.
39. Ananthakrishnan, R.; Kaneko, M.; Hwang, Y.C.; Quadri, N.; Gomez, T.; Li, Q.; Caspersen, C.; Ramasamy, R. Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore. Am. J. Physiol. Heart Circ. Physiol., 2009, 296(2), H333-341.
40. Tracey, W.R.; Magee, W.P.; Ellery, C.A.; MacAndrew, J.T.; Smith, A.H.; Knight, D.R.; Oates, P.J. Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury. Am. J. Physiol. Heart Circ. Physiol., 2000, 279(4), H1447-1452.
41. Shinmura, K.; Bolli, R.; Liu, S.Q.; Tang, X.L.; Kodani, E.; Xuan, Y.T.; Srivastava, S.; Bhatnagar, A. Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. Circ. Res., 2002, 91(3), 240-246.
42. Kaiserova, K.; Tang, X.L.; Srivastava, S.; Bhatnagar, A. Role of nitric oxide in regulating aldose reductase activation in the ischemic heart. J. Biol. Chem., 2008, 283(14), 9101-9112.
43. Iwata, K.; Matsuno, K.; Nishinaka, T.; Persson, C.; Yabe-Nishimura, C. Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. J. Pharmacol. Sci., 2006, 102(1), 37-46.
44. Lo, A.C.; Cheung, A.K.; Hung, V.K.; Yeung, C.M.; He, Q.Y.; Chiu, J.F.; Chung, S.S.; Chung, S.K. Deletion of aldose reductase leads to protection against cerebral ischemic injury. J. Cereb. Blood Flow Metab., 2007, 27(8), 1496-1509.
45. Tang, W.H.; Wu, S.; Wong, T.M.; Chung, S.K.; Chung, S.S. Polyol pathway mediates iron-induced oxidative injury in ischemicreperfused rat heart. Free Radic. Biol. Med., 2008, 45(5), 602-610.
46. Lee, A.Y.; Chung, S.S. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J., 1999, 13, 23-30.
47. Chung, S.S.; Ho, E.C.; Lam, K.S.; Chung, S.K. Contribution of polyol pathway to diabetes-induced oxidative stress. J. Am. Soc. Nephrol., 2003, 14(8), S233-236.
48. Ho, E.C.; Lam, K.S.; Chen, Y.S.; Yip, J.C.; Arvindakshan, M.; Yamagishi, S.; Yagihashi, S.; Oates, P.J.; Ellery, C.A.; Chung, S.S.; Chung, S.K. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes, 2006, 55(7), 1946-1953.
49. Obrosova, I.G.; Minchenko, A.G.; Vasupuram, R.; White, L.; Abatan, O.I.; Kumagai, A.K.; Frank, R.N.; Stevens, M.J. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes, 2003, 52(3), 864-871.
50. Li, Q.; Hwang, Y.C.; Ananthakrishnan, R.; Oates, P.J.; Guberski, D.; Ramasamy, R. Polyol pathway and modulation of ischemiareperfusion injury in Type 2 diabetic BBZ rat hearts. Cardiovasc. Diabetol., 2008, 7, 33.
51. Srivastava, S.; Chandrasekar, B.; Bhatnagar, A.; Prabhu, S.D. Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: role of aldose reductase. Am. J. Physiol. Heart Circ. Physiol., 2002, 283(6), H2612-2619.
52. Yang, J.; Moravec, C.S.; Sussman, M.A.; DiPaola, N.R.; Fu, D.; Hawthorn, L.; Mitchell, C.A.; Young, J.B.; Francis, G.S.; McCarthy, P.M.; Bond, M. Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation, 2000, 102(25), 3046-3052.
53. Srivastava, S.; Ramana, K.V.; Tammali, R.; Srivastava, S.K.; Bhatnagar, A. Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells. Diabetes, 2006, 55(4), 901-910.
54. Campbell, M.; Trimble, E.R. Modification of PI3K-and MAPKdependent chemotaxis in aortic vascular smooth muscle cells by protein kinase C betaII. Circ. Res., 2005, 96(2), 197-206.
55. Ramana, K.V.; Friedrich, B.; Srivastava, S.; Bhatnagar, A.; Srivastava, S.K. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes, 2004, 53(11), 2910-2920.
56. Ramana, K.V.; Chandra, D.; Srivastava, S.; Bhatnagar, A.; Aggarwal, B.B.; Srivastava, S.K. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J. Biol. Chem., 2002, 277(35), 32063-32070.
57. Ruef, J.; Liu, S.Q.; Bode, C.; Tocchi, M.; Srivastava, S.; Runge, M.S.; Bhatnagar, A. Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. Arterioscler. Thromb. Vasc. Biol., 2000, 20(7), 1745-1752.
58. Ramana, K.V.; Tammali, R.; Reddy, A.B.; Bhatnagar, A.; Srivastava, S.K. Aldose reductase-regulated tumor necrosis factor-alpha production is essential for high glucose-induced vascular smooth muscle cell growth. Endocrinology, 2007, 148(9), 4371-4384.
59. Blackwell, K.A.; Sorenson, J.P.; Richardson, D.M.; Smith, L.A.; Suda, O.; Nath, K.; Katusic, Z.S. Mechanisms of aginginduced impairment of endothelium-dependent relaxation: role of tetrahydrobiopterin. Am. J. Physiol. Heart Circ. Physiol., 2004, 287(6), H2448-H2453.
60. Brandes, R.P.; Fleming, I.; Busse, R. Endothelial aging. Cardiovasc. Res., 2005, 66(2), 286-294.
61. Chinellato, A.; Pandolfo, L.; Ragazzi, E.; Zambonin, M.R.; Froldi, G.; De Biasi, M.; Caparrotta, L.; Fassina, G. Effect of age on rabbit aortic responses to relaxant endothelium-dependent and endothelium independent agents. Blood Vessels, 1991, 28(5), 358-365.
62. Csiszar, A.; Ungvari, Z.; Edwards, J.G.; Kaminski, P.; Wolin, M.S.; Koller, A.; Kaley, G. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ. Res., 2002, 90(11), 1159-1166.
63. Geary, G.G.; Buchholz, J.N. Selected contribution: effects of aging on cerebrovascular tone and [Ca2+]i. J. Appl. Physiol., 2003, 95(4), 1746-1754.
64. Hongo, K.; Nakagomi, T.; Kassell, N.F.; Sasaki, T.; Lehman, M.; Vollmer, D.G.; Tsukahara, T.; Ogawa, H.; Torner, J. Effects of aging and hypertension on endothelium-dependent vascular relaxation in rat carotid artery. Stroke, 1988, 19(12), 892-897.
65. Kung, C.F.; Luscher, T.F. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension, 1995, 25(2), 194-200.
66. Muller-Delp, J.; Spier, S.A.; Ramsey, M.W.; Lesniewski, L.A.; Papadopoulos, A.; Humphrey, J.D.; Delp, M.D. Effects of aging on vasoconstrictor and mechanical properties of rat skeletal muscle arterioles. Am. J. Physiol. Heart Circ. Physiol., 2002, 282(4), H1843-H1854.
67. Murohara, T.; Yasue, H.; Ohgushi, M.; Sakaino, N.; Jougasaki, M. Age related attenuation of the endothelium dependent relaxation to noradrenaline in isolated pig coronary arteries. Cardiovasc. Res., 1991, 25(12), 1002-1009.
68. Al-Shaer, M.H.; Choueiri, N.E.; Correia, M.L.; Sinkey, C.A.; Barenz, T.A.; Haynes, W.G. Effects of aging and atherosclerosis on endothelial and vascular smooth muscle function in humans. Int. J. Cardiol., 2006, 109(2), 201-206.
69. Headrick, J.P. Aging impairs functional, metabolic and ionic recovery from ischemia-reperfusion and hypoxia-reoxygenation. J. Mol. Cell Cardiol., 1998, 30(7), 1415-1430.
70. Kates, A.M.; Herrero, P.; Dence, C.; Soto, P.; Srinivasan, M.; Delano, D.G.; Ehsani, A.; Gropler, R.J. Impact of aging on substrate metabolism by the human heart. J. Am. Coll. Cardiol., 2003, 41(2), 293-299.
71. McMillin, J.B.; Taffet, G.E.; Taegtmeyer, H.; Hudson, E.K.; Tate, C.A. Mitochondrial metabolism and substrate competition in the aging Fischer rat heart. Cardiovasc. Res. 1993, 27(12), 2222-2228.
72. Hallam, K.M.; Li, Q.; Ananthakrishnan, R.; Kalea, A.; Zou, Y.S.; Vedantham, S.; Schmidt, A.M.; Yan, S.F.; Ramasamy, R. Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell, 2010, 9(5), 776-784.
73. Ananthakrishnan, R.; Li, Q.; Gomes, T.; Schmidt, A.M.; Ramasamy, R. Aldose reductase pathway contributes to vulnerability of aging myocardium to ischemic injury. Exp. Gerontol., 2011, 46(9), 762-767.
74. Mylari, B.L.; Beyer, T.A.; Siegel, T.W. A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners. J. Med. Chem., 1991, 34(3), 1011-1018.
75. Sarges, R.; Oates, P.J. Aldose reductase inhibitors: recent developments. Prog. Drug Res., 1993, 40, 99-161.
76. Alexiou, P.; Pegklidou, K.; Chatzopoulou, M.; Nicolaou, I.; Demopoulos, V.J. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr. Med. Chem., 2009, 16(6), 734-752.
77. Johnson, B.F.; Nesto, R.W.; Pfeifer, M.A.; Slater, W.R.; Vinik, A.I.; Chyun, D.A.; Law, G.; Wackers, F.J.; Young, L.H. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care, 2004, 27(2), 448-454.
78. Didangelos, T.P.; Athyros, V.G.; Karamitsos, D.T.; Papageorgiou, A.A.; Kourtoglou, G.I.; Kontopoulos, A.G. Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. Clin. Drug Investig., 1998, 15(2), 111-121.
79. Passariello, N.; Sepe, J.; Marrazzo, G.; De Cicco, A.; Peluso, A.; Pisano, M.C.; Sgambato, S.; Tesauro, P.; D'Onofrio, F. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care, 1993, 16(5), 789-795.
80. Iso, K.; Tada, H.; Kuboki, K.; Inokuchi, T. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J. Diabetes Complications, 2001, 15(5), 241-244.